Characterization of the non-fibrillar α-synuclein oligomers.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Protein Peptide Letters

• Publication date

  2011-02-28

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2174/092986611794578332PMID 20858207
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions.

  2010cited by this paper
• Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation?

  2009cited by this paper
• Molecular mechanisms underlying the flavonoid-induced inhibition of alpha-synuclein fibrillation.

  2009cited by this paper
• At low concentrations, 3,4-dihydroxyphenylacetic acid (DOPAC) binds non-covalently to alpha-synuclein and prevents its fibrillation.

  2009cited by this paper
• Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein.

  2009cited by this paper
• Alpha-synuclein misfolding and neurodegenerative diseases.

  2008cited by this paper
• Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein.

  2008cited by this paper
• Thioflavin T as a molecular rotor: fluorescent properties of thioflavin T in solvents with different viscosity.

  2008cited by this paper
• Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation

  2007cited by this paper
• Study on the binding of Thioflavin T to beta-sheet-rich and non-beta-sheet cavities.

  2007cited by this paper
• Role of Different Regions of α-Synuclein in the Assembly of Fibrils†

  2007cited by this paper
• Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation.

  2007cited by this paper
• GM1 specifically interacts with alpha-synuclein and inhibits fibrillation.

  2007cited by this paper
• Effect of 4-Hydroxy-2-nonenal Modification on α-Synuclein Aggregation*

  2007cited by this paper
• Spectral properties of thioflavin T in solvents with different dielectric properties and in a fibril-incorporated form.

  2007cited by this paper
• Role of different regions of alpha-synuclein in the assembly of fibrils.

  2007cited by this paper
• Study on the binding of Thioflavin T to β-sheet-rich and non- β-sheet cavities

  2007cited by this paper
• GM1 Specifically Interacts with α-Synuclein and Inhibits Fibrillation†

  2007cited by this paper
• Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.

  2007cited by this paper
• Characterization of oligomers during alpha-synuclein aggregation using intrinsic tryptophan fluorescence.

  2006cited by this paper
• Secondary structure of alpha-synuclein oligomers: characterization by raman and atomic force microscopy.

  2006cited by this paper
• The aggregation and fibrillation of alpha-synuclein.

  2006cited by this paper
• The Aggregation and Fibrillation of α-Synuclein

  2006cited by this paper
• Secondary Structure of α-Synuclein Oligomers: Characterization by Raman and Atomic Force Microscopy

  2006cited by this paper
• Characterization of oligomeric intermediates in alpha-synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F alpha-synuclein.

  2005cited by this paper
• Effects of nitration on the structure and aggregation of α-synuclein

  2005cited by this paper
• Characterization of Oligomeric Intermediates in α-Synuclein Fibrillation: FRET Studies of Y125W/Y133F/Y136F α-Synuclein

  2005cited by this paper
• The biochemistry of Parkinson's disease.

  2005cited by this paper
• Early Events in the Fibrillation of Monomeric Insulin*

  2005cited by this paper
• Effects of nitration on the structure and aggregation of alpha-synuclein.

  2005cited by this paper
• Calcium(II) selectively induces α‐synuclein annular oligomers via interaction with the C‐terminal domain

  2004cited by this paper
• The Flavonoid Baicalein Inhibits Fibrillation of α-Synuclein and Disaggregates Existing Fibrils*

  2004cited by this paper
• The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia

  2004cited by this paper
• Association between cardiac denervation and parkinsonism caused by α‐synuclein gene triplication

  2004cited by this paper
• Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications.

  2004cited by this paper
• Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication.

  2004cited by this paper
• The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils.

  2004cited by this paper
• Rapid self-assembly of α-synuclein observed by in situ atomic force microscopy

  2004cited by this paper
• Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications

  2004cited by this paper
• Rapid self-assembly of alpha-synuclein observed by in situ atomic force microscopy.

  2004cited by this paper
• Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease

  2003cited by this paper
• A Protein-Chameleon: Conformational Plasticity of α-Synuclein, a Disordered Protein Involved in Neurodegenerative Disorders

  2003cited by this paper
• The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation.

  2003cited by this paper
• Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.

  2003cited by this paper
• Conformational behavior and aggregation of alpha-synuclein in organic solvents: modeling the effects of membranes.

  2003cited by this paper
• Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders.

  2003cited by this paper
• Lipid binding inhibits alpha-synuclein fibril formation.

  2003cited by this paper
• Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta.

  2003cited by this paper
• Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β

  2003cited by this paper
• Structural transformations of oligomeric intermediates in the fibrillation of the immunoglobulin light chain LEN.

  2003cited by this paper
• alpha-Synuclein locus triplication causes Parkinson's disease.

  2003cited by this paper
• Parkinson's Disease and Related α‐Synucleinopathies Are Brain Amyloidoses

  2003cited by this paper
• The Association of α-Synuclein with Membranes Affects Bilayer Structure, Stability, and Fibril Formation*

  2003cited by this paper
• Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.

  2003cited by this paper
• Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers.

  2003cited by this paper
• Lipid Binding Inhibits α-Synuclein Fibril Formation*

  2003cited by this paper
• The N-Terminal Repeat Domain of α-Synuclein Inhibits β-Sheet and Amyloid Fibril Formation†

  2003cited by this paper
• Nitration inhibits fibrillation of human α‐synuclein in vitro by formation of soluble oligomers

  2003cited by this paper
• α-Synuclein Locus Triplication Causes Parkinson's Disease

  2003cited by this paper
• Climate change (Communication arising): Recent temperature trends in the Antarctic

  2002influential reference
• Neurodegenerative disease: Amyloid pores from pathogenic mutations

  2002cited by this paper
• Membrane-bound α-Synuclein Has a High Aggregation Propensity and the Ability to Seed the Aggregation of the Cytosolic Form*

  2002cited by this paper
• Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes.

  2002influential reference
• Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.

  2002cited by this paper
• Elucidation of the Molecular Mechanism during the Early Events in Immunoglobulin Light Chain Amyloid Fibrillation

  2002cited by this paper
• Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease

  2002cited by this paper
• Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism.

  2002cited by this paper
• Effect of Association State and Conformational Stability on the Kinetics of Immunoglobulin Light Chain Amyloid Fibril Formation at Physiological pH*

  2002cited by this paper
• Parkinson's disease and other alpha-synucleinopathies.

  2001cited by this paper
• Parkinsons Disease and other α-Synucleinopathies

  2001cited by this paper
• Synucleinopathies: clinical and pathological implications.

  2001cited by this paper
• Stabilization of Partially Folded Conformation during α-Synuclein Oligomerization in Both Purified and Cytosolic Preparations*

  2001cited by this paper
• Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?

  2001cited by this paper
• Residual Structure and Dynamics in Parkinson's Disease-associated Mutants of α-Synuclein*

  2001cited by this paper
• Conformational properties of alpha-synuclein in its free and lipid-associated states.

  2001cited by this paper
• Evidence for a Partially Folded Intermediate in α-Synuclein Fibril Formation*

  2001cited by this paper
• Alpha-synuclein and neurodegenerative diseases

  2001cited by this paper
• Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies.

  2000cited by this paper
• alpha-Synuclein membrane interactions and lipid specificity.

  2000cited by this paper
• Dityrosine Cross-linking Promotes Formation of Stable α-Synuclein Polymers

  2000cited by this paper
• Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants.

  2000cited by this paper
• High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation

  2000cited by this paper
• α-Synuclein Membrane Interactions and Lipid Specificity*

  2000cited by this paper
• The α‐Synucleinopathies: Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy

  2000cited by this paper
• Accelerated Oligomerization by Parkinson's Disease Linked α‐Synuclein Mutants

  2000cited by this paper
• Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.

  2000cited by this paper
• The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.

  2000cited by this paper
• Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.

  1999cited by this paper
• AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease

  1998cited by this paper
• α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies

  1998cited by this paper
• Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies

  1998cited by this paper
• Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies.

  1998cited by this paper
• Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease

  1998cited by this paper
• Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

  1998cited by this paper
• alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.

  1998cited by this paper
• Alpha-synuclein in Lewy bodies.

  1997cited by this paper
• Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

  1997cited by this paper
• α-Synuclein in Lewy bodies

  1997cited by this paper
• Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease

  1997cited by this paper
• Fluorometric examination of tissue amyloid fibrils in murine senile amyloidosis: use of the fluorescent indicator, thioflavine T.

  1990cited by this paper

• Advances in Synchrotron Radiation‐Based Vacuum‐Ultraviolet Circular Dichroism for Biomolecular Structural Analysis

  2026cites this paper
• Small molecule inhibitors targeting alpha-synuclein aggregation: Progress and future outlook.

  2025cites this paper
• Elucidation of cytotoxicity of α-Synuclein fibrils on immune cells.

  2024cites this paper
• Elucidation of molecular mechanisms by which amyloid β1-42 fibrils exert cell toxicity.

  2024cites this paper
• Salt-Induced Hydrophobic C-Terminal Region of α-Synuclein Triggers Its Fibrillation under the Mimic Physiologic Condition.

  2024cites this paper
• Fibrillisation of faba bean protein isolate by thermosonication for process efficacy: microstructural characteristics, assembly behaviour, and physicochemical properties

  2024cites this paper
• Macrophages and Natural Killers Degrade α-Synuclein Aggregates

  2024cites this paper
• LRP10 and α-synuclein transmission in Lewy body diseases

  2024cites this paper
• Modulation of α-synuclein aggregation amid diverse environmental perturbation

  2024cites this paper
• Phospholipids and Cholesterol Determine Molecular Mechanisms of Cytotoxicity of α-Synuclein Oligomers and Fibrils.

  2024cites this paper
• The Role of α-Synuclein in Etiology of Neurodegenerative Diseases

  2024cites this paper
• Nanoscale imaging of individual amyloid aggregates extracted from brains of Alzheimer and Parkinson patients reveals presence of lipids in α‐synuclein but not in amyloid β1–42 fibrils

  2023cites this paper
• LRP10 as a novel α-synuclein regulator in Lewy body diseases

  2023cites this paper
• Lipids uniquely alter rates of insulin aggregation and lower toxicity of amyloid aggregates.

  2022cites this paper
• Lipids uniquely alter secondary structure and toxicity of lysozyme aggregates

  2022cites this paper
• Nanoscale Structural Analysis of a Lipid-Driven Aggregation of Insulin.

  2022cites this paper
• Phosphatidylcholine and Phosphatidylserine Uniquely Modify the Secondary Structure of α-Synuclein Oligomers Formed in Their Presence at the Early Stages of Protein Aggregation.

  2022cites this paper
• Nanoscale Characterization of Parallel and Antiparallel β-Sheet Amyloid Beta 1-42 Aggregates.

  2022cites this paper
• Nanomechanical Stability of Aβ Tetramers and Fibril-like Structures: Molecular Dynamics Simulations

  2021cites this paper
• The role of amyloids in Alzheimer's and Parkinson's diseases.

  2021cites this paper
• Single-molecule studies of amyloid proteins: from biophysical properties to diagnostic perspectives

  2020cites this paper
• The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges

  2020cites this paper
• High-Speed Atomic Force Microscopy Reveals the Structural Dynamics of the Amyloid-β and Amylin Aggregation Pathways

  2020cites this paper
• Structure Specific Neuro-toxicity of α-Synuclein Oligomer

  2020cites this paper
• Oligomers, fibrils and aggregates formed by alpha-synuclein: role of solution conditions

  2020cites this paper
• Iron-mediated interaction of alpha synuclein with lipid raft model membranes.

  2020cites this paper
• Nanomechanical properties of steric zipper globular structures

  2019cites this paper
• α-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson's disease.

  2019cites this paper
• Atomic force microscopy for single molecule characterisation of protein aggregation

  2019cites this paper
• Salivary alpha-synuclein in the diagnosis of Parkinson's disease and Progressive Supranuclear Palsy.

  2019cites this paper
• Posttranslational modifications and proteinopathies: how guardians of the proteome are defeated

  2019cites this paper
• In vitro models of synucleinopathies: informing on molecular mechanisms and protective strategies

  2019cites this paper
• Amyloid fibrils prepared using an acetylated and methyl amidated peptide model of the α-Synuclein NAC 71–82 amino acid stretch contain an additional cross-β structure also found in prion proteins

  2019cites this paper
• Identification and nanomechanical characterization of the fundamental single-strand protofilaments of amyloid α-synuclein fibrils

  2018cites this paper
• Pre-aggregation kinetics and intermediates of α-synuclein monitored by the ESIPT probe 7MFE

  2017cites this paper
• AFM-Based Single Molecule Techniques: Unraveling the Amyloid Pathogenic Species

  2016cites this paper
• Formation and Characterization of α-Synuclein Oligomers.

  2016cites this paper
• Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson’s Disease

  2016cites this paper
• Stabilization of α-Synuclein Fibril Clusters Prevents Fragmentation and Reduces Seeding Activity and Toxicity.

  2016cites this paper
• Influence of the β-sheet content on the mechanical properties of aggregates during amyloid fibrillization.

  2015cites this paper
• New Insights Into Amyloid Formation and Structure by Innovative Atomic Force Microscopy Methods

  2015cites this paper
• Protein Misfolding and Amyloid Formation in Alzheimer’s Disease

  2015cites this paper
• High stability and cooperative unfolding of α-synuclein oligomers.

  2014cites this paper
• Molecular Mechanisms of Protein Misfolding

  2014cites this paper
• The role of alpha-synuclein phosphorylation in synucleinopathies

  2014cites this paper
• Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus.

  2014cites this paper
• The role of stable α-synuclein oligomers in the molecular events underlying amyloid formation.

  2014cites this paper
• Exploring the accessible conformations of N‐terminal acetylated α‐synuclein

  2013cites this paper
• Biophysical Characterization of α-Synuclein and Rotenone Interaction

  2013cites this paper
• Structural and Compositional Information about Pre‐Amyloid Oligomers

  2013cites this paper
• Oligomers of α-synuclein in the pathogenesis of Parkinson's disease

  2012cites this paper
• Α-synuclein misfolding and Parkinson's disease.

  2012cites this paper
• α Aggregation and Modulating Factors

  2012cites this paper
• Role of α‐synuclein penetration into the membrane in the mechanisms of oligomer pore formation

  2012cites this paper
• α-Synuclein aggregation and modulating factors.

  2012cites this paper
• α-Synuclein Reactive Antibodies as Diagnostic Biomarkers in Blood Sera of Parkinson's Disease Patients

  2011cites this paper
• Drug targets from genetics: α-synuclein.

  2011cites this paper
• Drug Targets from Genetics: Alpha-Synuclein

  2011cites this paper